Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

NatureWise Biotech & Medicals Corporation (4732.TWO)

Compare
19.65
-0.20
(-1.01%)
At close: 2:57:11 PM GMT+8
Loading Chart for 4732.TWO
  • Previous Close 19.85
  • Open 18.80
  • Bid 18.75 x --
  • Ask 19.45 x --
  • Day's Range 17.85 - 20.05
  • 52 Week Range 17.40 - 27.50
  • Volume 110,816
  • Avg. Volume 47,986
  • Market Cap (intraday) 1.102B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) 72.78
  • EPS (TTM) 0.27
  • Earnings Date --
  • Forward Dividend & Yield 0.18 (0.89%)
  • Ex-Dividend Date Aug 27, 2024
  • 1y Target Est --

NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL Taiwan green propolis; and NBM-BMX, an oral softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei, Taiwan.

www.naturewise.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4732.TWO

View More

Performance Overview: 4732.TWO

Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4732.TWO
20.77%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
17.06%

1-Year Return

4732.TWO
19.42%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.16%

3-Year Return

4732.TWO
45.01%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
11.55%

5-Year Return

4732.TWO
11.28%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
85.71%

Compare To: 4732.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4732.TWO

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    1.11B

  • Enterprise Value

    628.05M

  • Trailing P/E

    72.88

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.02

  • Price/Book (mrq)

    1.75

  • Enterprise Value/Revenue

    2.80

  • Enterprise Value/EBITDA

    23.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.02%

  • Return on Assets (ttm)

    0.72%

  • Return on Equity (ttm)

    2.22%

  • Revenue (ttm)

    224.58M

  • Net Income Avi to Common (ttm)

    15.76M

  • Diluted EPS (ttm)

    0.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    493.91M

  • Total Debt/Equity (mrq)

    0.86%

  • Levered Free Cash Flow (ttm)

    -21.46M

Research Analysis: 4732.TWO

View More

Company Insights: 4732.TWO

Research Reports: 4732.TWO

View More

People Also Watch